December 14, 2022 – Florence, Italy Baebies today announced it is expanding its partnership with medical device supplier Medical Horizons S.r.L to help bring newborn screening solutions to a greater …
DURHAM, N.C. – (November 9, 2022) – Baebies has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its rapid, point-of-care test for glucose-6-phosphate dehydrogenase (G6PD) deficiency. The test …
Baebies Partners with Medical Horizons to Bring SEEKER Newborn Screening Platform to Italy Meyer Children’s Hospital in Florence becomes first screening location FLORENCE, Italy, May 10, 2022 – Baebies®, a …
Baebies was recently awarded $2.7 million in a Phase IIB SBIR grant from the National Institutes of Health (NIH). This award supports validation, clinical evaluation, and FDA submission of a rapid test panel for near-patient heparin monitoring. This project is a continuation of a long-standing collaboration with Boston Children’s Hospital.
Baebies announced today that CARB-X has awarded the company up to $11.6 million in non-dilutive funding. This funding will support the development of a near-patient and rapid diagnostic platform for sepsis – specially focused on addressing the unique needs of neonatal and pediatric populations.
Baebies has delivered 10 million tests to newborn screening labs around the world since the company was founded. This milestone translates to 10 million chances to provide a healthy start. Learn more about Baebies mission and growth.
Baebies was selected as the winner of the AACC Disruptive Technology Award by a panel of expert judges at the #2020AACC Annual Meeting. During the virtual competition, Baebies presented FINDER®, a diagnostic platform featuring a toaster-sized instrument and disposable cartridge.
Baebies has been named a finalist for the 2020 American Association for Clinical Chemistry’s (AACC) Disruptive Technology Award for FINDER®, a near-patient testing platform. As a growth-stage company developing diagnostic products to provide a healthy start for children everywhere, Baebies FINDER tests for diseases from low blood volume (50 µL) with a turn-around time of approximately 15 minutes after sample introduction.
Baebies, a growth-stage company developing diagnostic products to provide a healthy start for children everywhere, announced today that it has met all requirements for CE mark under the IVD Directive (98/79/EC) for newborn screening assays on SEEKER for galactosemia and biotinidase deficiency.
Baebies announced today the submission of FINDER G6PD to the U.S. Food and Drug Administration (FDA). FINDER™, a near-patient testing platform, includes a toaster-sized instrument and a disposable cartridge, which tests for Glucose-6-Phosphate Dehydrogenase (G6PD) from low blood volume.
- Page 1 of 2